SCHEMBL15467686

SCHEMBL15467686

Cc1ccncc1N1CCc2ccc(F)c(NCC3CC3)c2C1=O

nearest known ligand 0.37

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.34
CYP11B2 P19099 6/20 0.33
GSK3A P49840 1/20 0.33
PDE9A O76083 1/20 0.33
KDM4C Q9H3R0 3/20 0.33
AOC3 Q16853 1/20 0.33
CYP11B1 P15538 5/20 0.32
CRHR1 P34998 1/20 0.32
P2RX7 Q99572 1/20 0.32
KCNH2 Q12809 1/20 0.31
HPGD P15428 1/20 0.31
CCNT1 O60563 1/20 0.31
CDK9 P50750 1/20 0.31
PDE4A P27815 1/20 0.30
PDE4B Q07343 1/20 0.30
PDE4C Q08493 1/20 0.30
PDE4D Q08499 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL798873 0.80 CYP11B2 (0.39) CYP17A1CYP11B2CYP11B1P2RX7
SCHEMBL15467685 0.77 CYP17A1 (0.35) CYP17A1CYP11B2CYP11B1P2RX7
SCHEMBL793691 0.76 P2RX7 (0.40) CYP17A1CYP11B2CYP11B1P2RX7
SCHEMBL793672 0.72 HTR2C (0.35) CYP17A1CYP11B2CYP11B1P2RX7
SCHEMBL12467032 0.70 CYP11B2 (0.52) CYP17A1CYP11B2CYP11B1P2RX7
SCHEMBL793787 0.70 CYP11B2 (0.35) CYP17A1CYP11B2PDE9AKDM4CCYP11B1
SCHEMBL807968 0.69 F10 (0.41)
SCHEMBL794188 0.68 PDE4A (0.36) CYP17A1CYP11B2P2RX7HPGDPDE4A
SCHEMBL807907 0.68 CYP11B2 (0.43) CYP17A1CYP11B2CYP11B1
SCHEMBL807995 0.68 CYP11B2 (0.42) CYP11B2CYP11B1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 CYP17A1 1/4885CYP11B2 30/4885GSK3A 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.